Commentary on Reconstituting Fibrinogen Concentrate to Maintain Blinding in a Double-blind, Randomized Trial in an Emergency Setting

Journal of Emergency Medicine

Volumn 50, Issue 1, 2016, Pages 104-107.e1

  Bruynseels, Daniel ^a   Solomon, Cristina ^b,c   Hallam, Angela ^d   Collins, Peter W ^d,e   Collis, Rachel E ^a   Hamlyn, Vincent ^a   Hall, Judith E ^a,e  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c CSL BEHRING GMBH   (Germany)

^d CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

^e CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

double blind method; fibrinogen; postpartum hemorrhage

Indexed keywords

FIBRINOGEN CONCENTRATE; PLACEBO; FIBRINOGEN; HEMOSTATIC AGENT;

ARTICLE; BLEEDING; DOUBLE BLIND PROCEDURE; EMERGENCY; HUMAN; OBSTETRIC HEMORRHAGE; PRESSURE; PRIORITY JOURNAL; SYRINGE; HEMORRHAGE; MEDICAL RESEARCH; METHODOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BIOMEDICAL RESEARCH; DOUBLE-BLIND METHOD; FIBRINOGEN; HEMORRHAGE; HEMOSTATICS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84952872137     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2015.09.017     Document Type: Article

References (7)

1. Copenhagen University Hospital, Denmark. Pilot randomized trial of fibrinogen in trauma haemorrhage. Bethesda, MD: National Library of Medicine (US). Available at: https://clinicaltrials.gov/show/NCT02344069 NLM Identifier: NCT00004451. Accessed June 7, 2015.
2. Sunnybrook Health Sciences Centre, Toronto, Canada. Fibrinogen in the initial Resuscitation of Severe Trauma (FiiRST). Bethesda, MD: National Library of Medicine (US). Available at: https://clinicaltrials.gov/show/NCT02203968 NLM Identifier: NCT02203968. Accessed June 7, 2015.
3. Laboratoire français de Fractionnement et de Biotechnologies, France. Fibrinogen in Haemorrhage of Delivery (FIDEL). Bethesda, MD: National Library of Medicine (US). Available at: https://clinicaltrials.gov/show/NCT02155725 NLM Identifier: NCT02155725. Accessed June 7, 2015.
4. N. Aawar, R. Alikhan, D. Bruynseels, and et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: study protocol for a randomised controlled trial Trials 16 2015 169
5. CSL Behring, Marburg, Germany. RiaSTAP® summary of product characteristics. Available at: http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/?prodName=RIASTAP%201G%20POWDER%20FOR%20SOLUTION%20FOR%20INJECTION%20OR%20INFUSION&subsName=HUMAN%20FIBRINOGEN&pageID=SecondLevel. Accessed April 30, 2014.
6. J.V. Karri, J.C. Cardenas, P.I. Johansson, and et al. In vitro efficacy of RiaSTAP® after rapid reconstitution J Surg Res 186 2014 586 587
7. The University of Queensland, Australia. Trial of meropenem versus piperacillin-tazobactam on mortality and clinical response (MERINO II). Bethesda, MD: National Library of Medicine (US). Available at: https://clinicaltrials.gov/show/NCT02437045 NLM Identifier: NCT02437045. Accessed June 7, 2015.